lence of Pasteurella haemolytica. Can. J. Vet. Res., 54 Suplmt:S48-S52. 27. Confer, A.W., Panciera, R.J. and Mosier, D.A., 1986. Serum antibodies to Pasteurella haemolytica lipopolysaccharide: relationship to experimental bovine pneumonic pasteurellosis. Am. J. Vet. Res., 47: 1134-1138. 28. Mosier, D.A., Simons, K.R., Confer, A.W., Panciera, R.J. and Clinkenbeard, K.D., 1990 Pasteurella haemolytica antigens associated with resistance to pneumonia pasteurellosis. Infect. Immun. 57: 711-716. 29. Donachie, W. and Gilmour, N.J.L., 1988. Sheep antibody response to cell wall antigens expressed in vivo by Pasteurella haemolytica serotype A2. FEMS Microbiol. Let., 56: 271-276. 30. Lainson, F.A., Harkins, D.C., Wilson, C.F., Sutherland, A.D., Murray, J.E., Donachie, W. and Baird, G.D., 1991. Identification and localization of an iron-regulated 35 kDa protein of Pasteurella haemolytica serotype A2, J Gen. Microbiol., 137: 219-226. 31. Gilmour, N.J.L., Donachie W., Sutherland. A.D., Gilmour, J.S., Jones, G.E. and Quirie, M., 1991. Vaccine containing iron-regulated proteins of Pasteurella haemolytica A2 enhances protection against experimental pasteurellosis in lambs. Vaccine, 9: 137-139. 32. Confer, A.W., McCraw, R.D., Durham, J.A., Morton, R.J. and Panciera, R.J., 1994. Serum antibody response of cattle to iron-regulated outer

membrane proteins of Pasteurella haemolytica A1. Vet. Immonopathol., in press. 33. Lo, R.Y.C., 1990 Molecular characterization of cytotoxins produced by Haemophilus, Actinobacillus, Pasteurella. Can. J. Vet. Res. 54 Supplm.:S33-S35. 34. Shewen, P.E. and Wilkie, B.N., 1988. Vaccination of calves with leukotoxic culture supernatant from Pasteurella haemolytica. Can. J. Vet. Res., 52: 30-36. 35. Conlon, J.A. and Shewen, P.E., 1991. Efficacy of recombinant leukotoxin in protection against pneumonic challenge with live Pasteurella haemolytica A1. Infect. & Immun., 59: 587-591. 36. Confer, A.W., Panciera, R.J., Gentry, M.J. and Fulton, R.W., 1986. Immunologic response and resistance to experimental pneumonic pasteurellosis in cattle vaccinated with varying doses of lyophilized Pasteurella haemolytica. Am. J. Vet. Res., 47: 1853-1857. 37. Zeman, D., Neiger, R., Nietfield, J., Miskimins, D., Libal, M., Johnson, D., Janke, B., Gates, C. and Forbes, K., 1993. Systemic Pasteurella haemolytica infection as a rare sequel to avirulent live Pasteurella haemolytica vaccination in cattle. J. Vet. Diagn. Invest., 5: 555-559. 38. Panciera, R.J. and Corstvet, R.E., 1984. Bovine pneumonic pasteurellosis: model for Pasteurella haemolyticaand Pasteurella multocida-induced pneumonia in cattle. Am. J. Vet. Res., 45: 2532-2537.

## **Technology Transfer Symposium**

## Design of Strategic Anthelmintic Control Programs in Cattle Using a Mathematical Model: *Paraban*

## Smith, G.<sup>1</sup>and Jacobsen, J.A.<sup>2</sup>

<sup>1</sup>University of Pennsylvania School of Veterinary Medicine Kennett Square, PA 19348, USA <sup>2</sup>Merck AgVet PO Box 2000 Rahway, NJ 07065, USA

The design of cost-effective practical parasite control programs is fundamental to achieving optimum productivity from grazing cattle. Strategic treatment regimens such as the 3, 8 and 13 program utilizing ivermectin or the 3 and 6 recommendation for conventional anthelminitics have been developed from systematic field trials. These recommendations are relatively inflexible as they do not allow for altered animal management schemes. The objective for development of the PARABAN program was to facilitate design of efficient parasite control measures that would account for distinct husbandry practices and allow recognition of the potential consequences of missed or altered timing of doses. Data on the population biology of Cooperia, Trichostrongylus, Haemonchus and Ostertagia permit the development of a model for the processes that regulate and control parasite abundance. Input of local climatic data, as well as locally identified patterns of inhibition, allow tailoring of the model to project epidemiology on a regional basis. Incorporation of data on anthelmintic efficacy allows comparison of different treatment strategies, according to management objectives identified by the user. Validation studies completed in Europe and South America and comparison of model projections with published field data from the United States and New Zealand suggest that the model has a sound base for use throughout the world as a guide in development of parasite control strategies. Informed use of such a model will provide an educational basis to facilitate responsible and cost effective use of anthelminitics.